Figure 9.

pOVA-PEG20 vaccination in presence of pre-existing T effector cells. In vitro generated OVA-specific Th1 cells were labeled with CFSE and transferred into BALB/c mice. After 24 h, recipients received i.v. PBS (control), 5 µg of pOVA or equimolar amounts of pOVA-PEG20. After four days, splenocytes were re-isolated and proliferation, IFN-γ and TNF production as well as Foxp3 expression was assessed using flow cytometry. (A) Proliferation (x-fold CFSE dilution). (B) OVA-TCR⁺ T cells among total CD4⁺ cells. (C) % IFN-γ producers among OVA-specific CD4⁺ cells. (D) % Foxp3⁺ cells among OVA-specific CD4⁺ cells. (E, F) Absolute number of antigen-specific IFNγ or Foxp3⁺ cells expressed as % of total CD4⁺. (A–F) Pooled data with mean ± SD from two independent experiments; n = 6. Non-marked comparisons are non-significant. Statistical testing was performed using the nonparametric Mann Whitney test and Holm-Bonferroni correction for multiple comparisons. (*) p < 0.05; (**) p < 0.01.